Korea's Green Cross Seeks To Unveil Injectable Flu Antiviral Peramivir Even Before KFDA Approval

SEOUL - With or without an approval from Korea FDA, South Korea's vaccine producer Green Cross is gearing up to launch its version of injectable antiviral peramivir, which was developed by BioCryst Pharmaceuticals for treatment of influenza